{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:46:24Z","timestamp":1790023584795,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T00:00:00Z","timestamp":1511827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["51402264"],"award-info":[{"award-number":["51402264"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672696"],"award-info":[{"award-number":["81672696"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Talents Fund","award":["2016000021223ZK18"],"award-info":[{"award-number":["2016000021223ZK18"]}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7152033"],"award-info":[{"award-number":["7152033"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Baiqianwan Talents Project, Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding support","award":["ZYLX201603"],"award-info":[{"award-number":["ZYLX201603"]}]},{"name":"Beijing Municipal Science & Technology Commission","award":["Z151100003915074"],"award-info":[{"award-number":["Z151100003915074"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00432-017-2550-z","type":"journal-article","created":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T07:55:13Z","timestamp":1511855713000},"page":"257-267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Analysis of TSC1 mutation spectrum in mucosal melanoma"],"prefix":"10.1007","volume":"144","author":[{"given":"Meng","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5515-1015","authenticated-orcid":false,"given":"Yan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,28]]},"reference":[{"key":"2550_CR1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei IA, Schmidt S, Peshkin L (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:248","journal-title":"Nat Methods"},{"key":"2550_CR2","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622\u20133634. \n                        https:\/\/doi.org\/10.1200\/JCO.2001.19.16.3622","journal-title":"J Clin Oncol"},{"key":"2550_CR3","doi-asserted-by":"publisher","first-page":"6306","DOI":"10.1038\/sj.onc.1204009","volume":"19","author":"G Benvenuto","year":"2000","unstructured":"Benvenuto G et al (2000) The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 19:6306\u20136316. \n                        https:\/\/doi.org\/10.1038\/sj.onc.1204009","journal-title":"Oncogene"},{"key":"2550_CR4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/jso.23585","volume":"109","author":"SJ Byeon","year":"2014","unstructured":"Byeon SJ, Han N, Choi J, Kim MA, Kim WH (2014) Prognostic implication of TSC1 and mTOR expression in gastric carcinoma. J Surg Oncol 109:812\u2013817. \n                        https:\/\/doi.org\/10.1002\/jso.23585","journal-title":"J Surg Oncol"},{"key":"2550_CR5","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","volume":"83","author":"AE Chang","year":"1998","unstructured":"Chang AE, Karnell LH, Menck HR (1998) The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer the American Cancer Society Cancer. Cancer 83:1664\u20131678","journal-title":"Cancer"},{"key":"2550_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2407-11-85","volume":"11","author":"Z Chi","year":"2011","unstructured":"Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J (2011) Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11:85. \n                        https:\/\/doi.org\/10.1186\/1471-2407-11-85","journal-title":"BMC Cancer"},{"key":"2550_CR7","doi-asserted-by":"publisher","first-page":"8313","DOI":"10.1074\/jbc.C500451200","volume":"281","author":"H Chong-Kopera","year":"2006","unstructured":"Chong-Kopera H, Inoki K, Li Y, Zhu TQ, Garcia-Gonzalo FR, Rosa JL, Guan KL (2006) TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J Biol Chem 281:8313\u20138316. \n                        https:\/\/doi.org\/10.1074\/jbc.C500451200","journal-title":"J Biol Chem"},{"key":"2550_CR8","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA et al (2005) Distinct sets of genetic alterations in melanoma N. Engl J Med 353:2135\u20132147. \n                        https:\/\/doi.org\/10.1056\/NEJMoa050092","journal-title":"Engl J Med"},{"key":"2550_CR9","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1200\/JCO.2005.07.168","volume":"23","author":"DL Dai","year":"2005","unstructured":"Dai DL, Martinka M, Li G (2005) Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23:1473\u20131482. \n                        https:\/\/doi.org\/10.1200\/JCO.2005.07.168","journal-title":"J Clin Oncol"},{"key":"2550_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcdb.2016.01.025","volume":"52","author":"KM Dodd","year":"2016","unstructured":"Dodd KM, Dunlop EA (2016) Tuberous sclerosis\u2013A model for tumour growth Semin. Cell Dev Biol 52:3\u201311. \n                        https:\/\/doi.org\/10.1016\/j.semcdb.2016.01.025","journal-title":"Cell Dev Biol"},{"key":"2550_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/COC.0b013e31827b45d4","volume":"37","author":"RS Dronca","year":"2014","unstructured":"Dronca RS et al (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma a North Central Cancer Treatment Group Study, N0675. Am J Clin Oncol-Canc 37:369\u2013376. \n                        https:\/\/doi.org\/10.1097\/COC.0b013e31827b45d4","journal-title":"Am J Clin Oncol-Canc"},{"key":"2550_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/path.4204","volume":"230","author":"SJ Furney","year":"2013","unstructured":"Furney SJ et al (2013) Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol 230:261\u2013269. \n                        https:\/\/doi.org\/10.1002\/path.4204","journal-title":"J Pathol"},{"key":"2550_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/path.4176","volume":"230","author":"Y Guo","year":"2013","unstructured":"Guo Y, Chekaluk Y, Zhang J, Du J, Gray NS, Wu CL, Kwiatkowski DJ (2013) TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. J Pathol 230:17\u201327. \n                        https:\/\/doi.org\/10.1002\/path.4176","journal-title":"J Pathol"},{"key":"2550_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK et al (2017) Whole-genome landscapes of major. melanoma subtypes Nature 545:175\u2013180. \n                        https:\/\/doi.org\/10.1038\/nature22071","journal-title":"melanoma subtypes Nature"},{"key":"2550_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312734","author":"DW Ho","year":"2016","unstructured":"Ho DW et al. (2016) TSC1\/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication. Gut. \n                        https:\/\/doi.org\/10.1136\/gutjnl-2016-312734","journal-title":"Gut"},{"key":"2550_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1042\/BJ20080281","volume":"412","author":"J Huang","year":"2008","unstructured":"Huang J, Manning BD (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412:179\u2013190. \n                        https:\/\/doi.org\/10.1042\/BJ20080281","journal-title":"Biochem J"},{"key":"2550_CR17","doi-asserted-by":"publisher","first-page":"6356","DOI":"10.1038\/sj.onc.1205792","volume":"21","author":"E Im","year":"2002","unstructured":"Im E et al (2002) Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene 21:6356\u20136365. \n                        https:\/\/doi.org\/10.1038\/sj.onc.1205792","journal-title":"Oncogene"},{"key":"2550_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1126\/science.1226344","volume":"338","author":"G Iyer","year":"2012","unstructured":"Iyer G et al (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science 338:221. \n                        https:\/\/doi.org\/10.1126\/science.1226344","journal-title":"Science"},{"key":"2550_CR19","first-page":"479","volume":"10","author":"A Janus","year":"2005","unstructured":"Janus A, Robak T, Smolewski P (2005) The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 10:479\u2013498","journal-title":"Cell Mol Biol Lett"},{"key":"2550_CR20","doi-asserted-by":"publisher","first-page":"29930","DOI":"10.1074\/jbc.M402591200","volume":"279","author":"M Karbowniczek","year":"2004","unstructured":"Karbowniczek M, Cash T, Cheung M, Robertson GP, Astrinidis A, Henske EP (2004) Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem 279:29930\u201329937. \n                        https:\/\/doi.org\/10.1074\/jbc.M402591200","journal-title":"J Biol Chem"},{"key":"2550_CR21","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-10-2346","volume":"17","author":"Y Kong","year":"2011","unstructured":"Kong Y et al (2011) Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17:1684\u20131691. \n                        https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2346","journal-title":"Clin Cancer Res"},{"key":"2550_CR22","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/1078-0432.Ccr-15-1110","volume":"22","author":"Y Kong","year":"2016","unstructured":"Kong Y et al (2016) Analysis of mTOR gene aberrations in melanoma patients and evaluation of their sensitivity to PI3K-AKT-mTOR pathway inhibitors. Clin Cancer Res 22:1018\u20131027. \n                        https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1110","journal-title":"Clin Cancer Res"},{"key":"2550_CR23","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","volume":"21","author":"D Kuk","year":"2016","unstructured":"Kuk D et al (2016) Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of. First Metastasis Oncologist 21:848\u2013854. \n                        https:\/\/doi.org\/10.1634\/theoncologist.2015-0522","journal-title":"First Metastasis Oncologist"},{"key":"2550_CR24","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nprot.2009.86","volume":"4","author":"P Kumar","year":"2009","unstructured":"Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073","journal-title":"Nat Protoc"},{"key":"2550_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence MS et al (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495\u2013501. \n                        https:\/\/doi.org\/10.1038\/nature12912","journal-title":"Nature"},{"key":"2550_CR26","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4161\/cbt.12.12.18442","volume":"12","author":"SV Madhunapantula","year":"2011","unstructured":"Madhunapantula SV, Mosca PJ, Robertson GP (2011) The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther 12:1032\u20131049. \n                        https:\/\/doi.org\/10.4161\/cbt.12.12.18442","journal-title":"Cancer Biol Ther"},{"key":"2550_CR27","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1200\/JCO.2000.18.22.3782","volume":"18","author":"J Manola","year":"2000","unstructured":"Manola J, Atkins M, Ibrahim J, Kirkwood J (2000) Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18:3782\u20133793. \n                        https:\/\/doi.org\/10.1200\/JCO.2000.18.22.3782","journal-title":"J Clin Oncol"},{"key":"2550_CR28","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.2741\/1755","volume":"10","author":"F Meier","year":"2005","unstructured":"Meier F et al (2005) The RAS\/RAF\/MEK\/ERK and PI3K\/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10:2986\u20133001","journal-title":"Front Biosci"},{"key":"2550_CR29","first-page":"739","volume":"5","author":"M Mihajlovic","year":"2012","unstructured":"Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V (2012) Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 5:739\u2013753","journal-title":"Int J Clin Exp Pathol"},{"key":"2550_CR30","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1093\/hmg\/10.25.2889","volume":"10","author":"M Nellist","year":"2001","unstructured":"Nellist M, Verhaaf B, Goedbloed MA, Reuser AJ, van den Ouweland AM, Halley DJ (2001) TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex. Hum Mol Genet 10:2889\u20132898","journal-title":"Hum Mol Genet"},{"key":"2550_CR31","first-page":"4766","volume":"58","author":"TL Plank","year":"1998","unstructured":"Plank TL, Yeung RS, Henske EP (1998) Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 58:4766\u20134770","journal-title":"Cancer Res"},{"key":"2550_CR32","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","volume":"15","author":"FM Platt","year":"2009","unstructured":"Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA (2009) Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 15:6008\u20136017. \n                        https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0898","journal-title":"Clin Cancer Res"},{"key":"2550_CR33","first-page":"463s","volume":"24","author":"RD Rao","year":"2006","unstructured":"Rao RD et al (2006) Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J Clin Oncol 24:463s","journal-title":"J Clin Oncol"},{"key":"2550_CR34","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1093\/nar\/gkr407","volume":"39","author":"B Reva","year":"2011","unstructured":"Reva B, Antipin Y, Sander C (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39:e118","journal-title":"Nucleic Acids Res"},{"key":"2550_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","volume":"48","author":"L Si","year":"2012","unstructured":"Si L et al (2012) Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 48:94\u2013100. \n                        https:\/\/doi.org\/10.1016\/j.ejca.2011.06.056","journal-title":"Eur J Cancer"},{"key":"2550_CR36","doi-asserted-by":"publisher","first-page":"13571","DOI":"10.1073\/pnas.202476899","volume":"99","author":"AR Tee","year":"2002","unstructured":"Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J (2002) Tuberous sclerosis complex-1 and \u2013 2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99:13571\u201313576. \n                        https:\/\/doi.org\/10.1073\/pnas.202476899","journal-title":"Proc Natl Acad Sci USA"},{"key":"2550_CR37","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","volume":"13","author":"AR Tee","year":"2003","unstructured":"Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J (2003) Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward. Rheb Curr Biol 13:1259\u20131268. \n                        https:\/\/doi.org\/10.1016\/S0960-9822(03)00506-2","journal-title":"Rheb Curr Biol"},{"issue":"34","key":"2550_CR38","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","volume":"277","author":"M Slegtenhorst van","year":"1997","unstructured":"van Slegtenhorst M et al (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q. Science 277(34):805\u2013808","journal-title":"Science"},{"key":"2550_CR39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/hmg\/7.6.1053","volume":"7","author":"M Slegtenhorst van","year":"1998","unstructured":"van Slegtenhorst M et al (1998) Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 7:1053\u20131057. \n                        https:\/\/doi.org\/10.1093\/hmg\/7.6.1053","journal-title":"Hum Mol Genet"},{"key":"2550_CR40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nature13492","volume":"513","author":"Y Zhang","year":"2014","unstructured":"Zhang Y et al (2014) Coordinated regulation of protein synthesis and degradation by mTORC1. Nature 513:440\u2013443. \n                        https:\/\/doi.org\/10.1038\/nature13492","journal-title":"Nature"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2550-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2550-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2550-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T09:04:15Z","timestamp":1517475855000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2550-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,28]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["2550"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2550-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,28]]}}}